Catalyst Pharma ( (CPRX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Catalyst Pharmaceutical Partners’ stock has been on the rise due to a strong Q4 financial performance, marked by a 23.5% increase in revenue year-over-year, driven by robust sales of FIRDAPSE and the successful launch of AGAMREE. These positive developments, along with strategic moves like a favorable patent resolution with Teva and a strong cash position, have led analysts, including Stephens’ Sudan Loganathan, to raise their price targets. Despite challenges such as expected revenue declines for FYCOMPA due to patent expiry and increased SG&A expenses, the company’s strategic financial management and projected revenue growth for 2025 continue to bolster market confidence, even amid negative insider sentiment from recent sales.
More about Catalyst Pharma
YTD Price Performance: 0.65%
Average Trading Volume: 1,099,470
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.63B
For further insights into CPRX stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.